研究胃肠道间质瘤（GIST）患者肿瘤组织中整合素α2（ITGA2）的表达及临床意义。

收集2014年1月至2024年12月在新疆维吾尔自治区人民医院确诊并手术治疗的96例患者的GIST组织标本，术后病理报告中ITGA表达阳性的41例GIST患者组织标本作为ITGA（+），ITGA表达阴性的55例GIST患者组织标本作为ITGA（-），应用免疫组织化学测定肿瘤组织中ITGA2蛋白的表达，通过χ²检验比较2组间临床病理特征的差异，包括年龄、性别、肿瘤部位、浸润程度、肿瘤大小、肿瘤危险度分级、核分裂像计数及SMA、DOG-1、CD34、CD117、S-100、Desmin等标志物的表达。

96例GIST患者中ITGA2蛋白阳性表达率为42.7%（41/96）。ITGA2（+）组患者中肿瘤最大径> 5 cm的比例（63.4%，26/41）高于ITGA2（-）组（38.2%，21/55），高危患者的比例（58.5%，24/41）高于ITGA（-）组（27.3%，15/55），高核分裂像（>5/50 HPF）患者的比例（24.4%，10/41）高于ITGA（-）组（7.3%，4/55），差异具有统计学意义（χ²=13.486，P=0.004；χ²=10.518，P=0.001；χ²=5.525，P=0.019）。ITGA2阳性组中SMA阳性率（0，0/41）低于ITGA（-）组（18.2%，10/55），DOG-1阳性率（82.9%，34/41）高于ITGA(-)组（61.8%，34/55），差异具有统计学意义（χ²=8.322，P=0.004；χ²=5.066，P=0.024），然而，2组患者年龄、性别、肿瘤部位、浸润程度、CD34、CD117、S-100、Desmin表达等因素比较，组间差异均无统计学意义（P均>0.05）。

ITGA2在GIST组织内呈现高度表达，其高表达状态与肿瘤的风险等级紧密相关，可能成为GIST特异性治疗的新靶点。

To investigate the expression of integrin α2 (ITGA2) and its clinical significance in gastrointestinal stromal tumors (GIST).

A total of 96 surgically resected GIST tissue specimens were collected from patients diagnosed and surgically treated at the People’s Hospital of Xinjiang Uygur Autonomous Region between January 2014 and December 2024. Based on postoperative pathological reports, 41 patients with ITGA2-positive expression were assigned to the observation group, and 55 patients with ITGA2-negative expression were assigned to the control group. Immunohistochemistry (IHC) was performed to determine the expression of ITGA2 protein in the tumor tissues. Chi-square tests were used to compare differences in clinicopathological features between the two groups, including analysis of correlations between ITGA2 expression and age, gender, tumor location, depth of invasion, tumor size, tumor risk grade, mitotic count, and expression of SMA, DOG-1, CD34, CD117, S-100, and Desmin.

The positive expression rate of ITGA2 protein in 96 GIST patients was 42.7% (41/96). The proportion of patients with tumor maximum diameter >5 cm in the ITGA2-positive group was significantly higher than that in the ITGA2-negative group [63.4%(26/41) vs 38.2%(21/55), χ²=13.486, P=0.004). The proportion of high-risk patients in the ITGA2-positive group was significantly higher than that in the ITGA2-negative group [58.5%(24/41) vs 27.3%(15/55), χ²=10.518, P=0.001). The ITGA2-positive rate in patients with mitotic count >5/50 HPF was significantly higher than that in patients with mitotic count ≤5/50 HPF [71.4%(10/14) vs 37.8%(31/82), χ²=5.525, P=0.019]. The SMA-positive rate in the ITGA2-positive group was significantly lower than that in the ITGA2-negative group [0(0/41) vs 18.2%(10/55), χ²=8.322, P=0.004). The DOG-1-positive rate in the ITGA2-positive group was significantly higher than that in the ITGA2-negative group [82.9%(34/41) vs 61.8%(34/55), χ²=5.066, P=0.040]. There were no significant different with patient age, gender, tumor location, depth of invasion, or expression of CD34, CD117, S-100, and Desmin between two groups (all P>0.05).

ITGA2 is highly expressed in the tissues of gastrointestinal stromal tumor, and its high expression is closely related to the risk grade of the tumor, which may become a new target for the specific treatment of gastrointestinal stromal tumor.